Stockscreener 앱 받기
2.10
0.48%
0.01
시간 외 거래:
2.11
0.010
+0.48%
Lipocine Inc 주식(LPCN)의 최신 뉴스
Lipocine Inc. (LPCN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Lipocine (LPCN) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Lipocine stock price target maintained at $4 by H.C. Wainwright - Investing.com Nigeria
LPCN Reiterated by HC Wainwright & Co. -- Price Target Announced at $4.00 - GuruFocus
HC Wainwright & Co. reiterates Neutral rating on Lipocine, $4 price target - TradingView
H.C. Wainwright Maintains Lipocine(LPCN.US) With Hold Rating, Announces Target Price $4 - Moomoo
Why Lipocine Inc. (NASDAQ:LPCN) Is In Focus Now? - Kalkine Media
Lipocine Inc.Common Stock (Nasdaq:LPCN) Stock Quote - The Chronicle-Journal
Lipocine (NASDAQ: LPCN) shares slides from New York investor conference - Stock Titan
LPCN: LPCN 1154 is poised to set a new standard in rapid, well-tolerated postpartum depression therapy - TradingView
Lipocine starts second Phase III for postpartum depression drug after first trial misses endpoint - AllSci
Lipocine initiates phase 3 trial for postpartum depression drug - Investing.com
Lipocine initiates phase 3 trial for postpartum depression drug By Investing.com - Investing.com Canada
Lipocine Announces Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression - PR Newswire
Lipocine Launches Phase 3 BLOOM Study for PPD - TipRanks
Lipocine launches BLOOM Phase 3 study of LPCN 1154 for PPD; plans ~120 patients, expects $1M/mo cash use - TradingView
Form 8K Lipocine Inc For: 14 September By Investing.com - Investing.com UK
Lipocine starts Phase 3 trial for oral postpart... - Pluang
Form 8K Lipocine Inc For: 11 September By Investing.com - Investing.com Australia
Lipocine Stock Price Forecast. Should You Buy LPCN? - StockInvest.us
Lipocine Inc (NASDAQ: LPCN) Share Price, LPCN Stock News, LPCN Share Price & Updates - Kalkine
Lipocine updates sales agent fee agreement with A.G.P./Alliance Global Partners - Investing.com
Lipocine Cuts ATM Sales Agent Fee to Up to 3.0% - Minichart
Lipocine Updates Sales Agreement Fee Structure with A.G.P. - TipRanks
Lipocine (LPCN) sets sales agent commissions at up to 3% - Stock Titan
Form 8K Lipocine Inc For: 10 September By Investing.com - Investing.com South Africa
Lipocine to present at H.C. Wainwright conferen... - Pluang
Lipocine to Present at the H.C. Wainwright 28th Annual Global Investment Conference - PR Newswire
Lipocine to Present at H.C. Wainwright Investment Conference - TipRanks
Form 8K Lipocine Inc For: 10 September - Investing.com India
Webcast to highlight Lipocine (LPCN) oral drug pipeline - Stock Titan
Lipocine (LPCN) Advances 3.06% to $2.35, Testing Key Resistance ZoneSeasonality Effect - vinanet.vn
Lipocine (LPCN) Jumps 5.35% to $2.27 as Buyers Target $2.38 ResistanceInside Day Breakout - dars.gov.et
Postpartum Depression Market to Evolve During the Forecast Period (2026-2036) with Breakthrough Treatments and Expanding Pipeline Assets | DelveInsight - Yahoo Finance
Lipocine (LPCN) Q2 2026 Results: The Bottom-Line Figure Beats Its Comparison for the Current Session; After Results: The Share Price Moves Only Slightly under the Current SnapshotGross Profit Margin - vinanet.vn
Lipocine (LPCN) adds Grissinger to pay panel at $7,500 a year - Stock Titan
Lipocine (LPCN) Q2 2026 Scorecard: EPS Comes in Above Forecast in Latest Trading; Price Reaction - vinanet.vn
Lipocine (LPCN) Q2 2026 Filing Snapshot: Reported EPS Tops Expectations in Latest Trading; Immediate Response: The Stock Ends Down 0.49% in the Current UpdateEarnings Preview - dars.gov.et
Lipocine Inc. (LPCN) Edges Higher to $2.12, Holding Above Key SupportAdvance Decline Volume - dars.gov.et
Lipocine (LPCN): Squadron funds report 810,000 shares, a 9.8% ownership stake - Stock Titan
LPCN Q2 2026 Earnings: Narrower-Than-Expected Loss Beats Consensus as Revenue Remains Absent - vinanet.vn
Weekly Recap: Q2 revenue drop and Brilzio partner search - TradingView
LPCN Q2 2026 Earnings: Loss Narrower Than Expected, Shares Ease 1.41%Energy Earnings Report - careplusvn.com
Lipocine Inc. (NASDAQ: LPCN) awards director 2,000 stock options - Stock Titan
Lipocine Inc. (LPCN) director Grissinger files initial ownership statement - Stock Titan
Lipocine Inc (LPCN) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
Lipocine files Form 3 initial beneficial ownership statement for director Michael Grissinger - Bitget
Lipocine Inc (LPCN) Stock News Today - TradingKey
LPCN Q1 2026 Earnings: Wider-than-Expected Loss Reflects Clinical-Stage SpendingProfit Warning Alert - dars.gov.et
Analysts Offer Insights on Healthcare Companies: Pfizer (PFE), Lipocine (LPCN) and High Tide (HITI) - The Globe and Mail
Lipocine (LPCN) Slips 1.8% to $2.13 as Biotech Stock Holds Above Key $2.02 SupportOvervalued Signals - dars.gov.et
A. G. P. Maintains Lipocine(LPCN.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Lipocine Inc (LPCN) Earnings Date & Reports & Earnings News - TradingKey
3.06%
2.55%
자본화:
|
볼륨(24시간):